METROPOLIS Metropolis Healthcare Q2 FY26 results (Jul–Sep 2025) and concall
Metropolis Healthcare reported strong Q2 FY26 results with Group revenue up 23% YoY and organic revenue growing 12%. Organic EBITDA margins expanded by 60 bps to 26.8%, driven by operational efficiencies and growth in TruHealth and Specialty segments. The company is focused on integrating recent acquisitions and expanding its collection center network, while managing the short-term margin dilution from acquired entities.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|
| Revenue | 11 | 4 | 23 | 23 |
| EBITDA | 72 | 62 | 90 | 108 |
| Net profit | 31 | 29 | 45 | 53 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
